StockNews.AI
MIRA
StockNews.AI
103 days

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

1. MIRA announces acquisition of SKNY targeting obesity, nicotine dependence. 2. SKNY will contribute $5 million at closing to MIRA.

M&A
+2.16%Current Return
VS
+0.66%S&P 500
$1.1605/08 08:05 AM EDTEvent Start
$1.18505/09 02:57 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition could enhance MIRA's product offerings and market position. Similar acquisitions in pharma have led to increased valuations and investor confidence.

How important is it?

The acquisition could significantly alter MIRA's growth trajectory and market perception. Strategic moves in expanding into obesity and nicotine markets are timely, considering rising health concerns.

Why Long Term?

The merger will take time to integrate and realize synergies, affecting long-term growth. Historical examples show successful acquisitions often take years to reflect in stock performance.

Related Companies

SKNY
With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred at closing. MIAMI, FLORIDA / ACCESS Newswire / May 8, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its Board of Directors has approved the planned acquisition of SKNY Pharmaceuticals, Inc. (the "Merger"), following the completion of independent valuation reports on both companies.

Related News